Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and pravastatin for relapsed leukemia post-HSCT in children
NCT02484261Phase 1Terminated
- Start
- May 2015
- Primary completion
- May 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of bortezomib and pravastatin in leukemia (2 arms). Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 3 years. Started May 2015; status: terminated.
02
Drugs
bortezomibpravastatin
03
Conditions
leukemia
Beyond the preview
Go deeper on NCT02484261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484261.